RESUMO
OBJECTIVE: The present study compared the efficacy of agomelatine and sertraline in the treatment of symptoms of depression/anxiety, diabetes self-care and metabolic control in a sample of depressed patients with non-optimally controlled type 2 diabetes mellitus (DM). METHOD: This was an observational open label study of 40 depressed patients with DM who were randomly assigned to receive either agomelatine or sertraline, and were assessed over a 4-month period for depression, anxiety, self-care, fasting plasma glucose, haemoglobin A1c and body weight. RESULTS: Lower anxiety and depression scores as well as higher self-care scores were measured in the agomelatine group compared with the sertraline group after 4 months of treatment. Although the main effects of treatment on final body weight and fasting plasma glucose were not significant, significantly lower final haemoglobin A1c levels were measured in the agomelatine group compared with the sertraline group. Both antidepressants were well tolerated and none of the patients dropped-out of the study. CONCLUSION: The main finding of the present small pilot study was that agomelatine may be a promising agent in the treatment of symptoms of depression and anxiety as well as in the improvement of health-related behaviours, in depressed patients with type 2 DM possibly offering some advantages over sertraline. However, the lack of a placebo control group limits the generalisability of the findings and warrants further studies.
Assuntos
Acetamidas/administração & dosagem , Antidepressivos/administração & dosagem , Transtorno Depressivo/tratamento farmacológico , Diabetes Mellitus Tipo 2/psicologia , Sertralina/administração & dosagem , Acetamidas/efeitos adversos , Adolescente , Adulto , Antidepressivos/efeitos adversos , Transtornos de Ansiedade/sangue , Transtornos de Ansiedade/tratamento farmacológico , Transtorno Depressivo/sangue , Diabetes Mellitus Tipo 2/sangue , Hemoglobinas Glicadas/metabolismo , Humanos , Pessoa de Meia-Idade , Projetos Piloto , Autocuidado , Sertralina/efeitos adversos , Resultado do Tratamento , Adulto JovemRESUMO
The present study examines quality of life (QoL) and psychiatric symptomatology prior to and upon completion of a 5-week in-patient detoxification programme with the aim to identify any changes produced following clinical intervention. A group of 46 alcohol-dependent individuals, who were consecutively admitted for detoxification in the Psychiatric Hospital of the University of Athens, were clinically-assessed at admission and just before discharge with DSM-IV, CIDI-WHO and with the Hamilton Depression and Anxiety Scales (HDRS, HARS) and the Global Assessment Scale (GAS) for depression, anxiety and overall functioning, respectively. In addition, the patients were invited to complete the World Health Organization Quality of Life WHOQOL-100 instrument. Differences between admission and discharge scores were examined using related sample t-tests. Correlations between the WHOQOL-100 scores and clinically-assessed symptomatology measures were performed. Regression analysis was conducted to investigate the correlation of clinical and socio-demographic variables with patient overall QoL. The results indicate that QoL scores increased at discharge in 16 out of the 24 WHOQOL-100 facets. In addition, patient-assessed status of health was significantly improved. Improvement was also observed in the symptomatology scales rated by the clinician, providing evidence for lower levels of depression, anxiety and a higher level of functioning. Moderate correlations were found between WHOQOL-100 domains and psychiatric symptomatology scales. Significant WHOQOL-100 gains at discharge and clinically-assessed improvement in the HDRS, HARS and GAS, provide evidence of the WHOQOL-100 instrument's sensitivity to changes in clinical condition. The WHOQOL-100 measurement may be suitable for detecting QoL deficits or therapeutic gains in alcohol-dependent patients and may prove useful to mental health professionals for treatment planning.
Assuntos
Alcoolismo/terapia , Indicadores Básicos de Saúde , Escalas de Graduação Psiquiátrica/normas , Qualidade de Vida/psicologia , Adulto , Idoso , Idoso de 80 Anos ou mais , Alcoolismo/psicologia , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Resultado do Tratamento , Organização Mundial da SaúdeRESUMO
OBJECTIVES: To evaluate the occurrence of Ulnar neuropathy at the elbow (UNE) among alcohol dependent subjects. METHOD: The study sample comprised 99 consecutive alcohol dependent subjects treated for detoxification voluntarily in the specialized unit of the Athens University Psychiatric Clinic in an inpatient basis. RESULTS: UNE was found in 51 subjects (51.5%): in 40.4% on the right side, in 44.6% on the left and in 20.1% on both. Polyneuropathy was diagnosed in 41.4% of the total sample. Statistical analysis showed UNE significantly associated with age of the subjects, age at alcohol dependence onset and duration of alcohol dependence. Was more frequent in men and the probability of UNE was lower in obese subjects. CONCLUSIONS: UNE is frequent among alcohol dependent subjects and they must be instructed to avoid abnormal postures and to protect their elbow while working with the elbows flexed and resting on a hard object.
Assuntos
Alcoolismo/epidemiologia , Condução Nervosa/fisiologia , Neuropatias Ulnares/epidemiologia , Adulto , Idoso , Alcoolismo/fisiopatologia , Comorbidade , Eletrodiagnóstico , Humanos , Masculino , Pessoa de Meia-Idade , Prevalência , Nervo Ulnar/fisiopatologia , Neuropatias Ulnares/diagnóstico , Neuropatias Ulnares/fisiopatologiaRESUMO
Anxiety and depression are frequently encountered 'collateral' symptoms in alcohol abusing subjects. The present study investigated the effect of detoxification on these symptoms over 4-5 weeks of abstinence from alcohol. Psychopathology and global functioning were assessed at baseline and at weekly intervals over this period from 28 alcoholics treated on an inpatient basis. At intake, they displayed high levels of anxiety and depression; also, global functioning was seriously impaired. Following detoxification, scores on all measures of psychopathology were notably reduced. These findings allude to the depression-inducing properties of alcohol, which should be considered in the differential diagnosis of mood symptoms in alcohol abusing individuals.
Assuntos
Consumo de Bebidas Alcoólicas/psicologia , Alcoolismo/psicologia , Alcoolismo/reabilitação , Transtornos de Ansiedade/psicologia , Transtorno Depressivo/psicologia , Adulto , Idoso , Alcoolismo/complicações , Transtornos de Ansiedade/complicações , Transtorno Depressivo/complicações , Feminino , Humanos , Pacientes Internados , Masculino , Pessoa de Meia-Idade , Escalas de Graduação Psiquiátrica , Estudos de Amostragem , TemperançaRESUMO
BACKGROUND: Social anxiety disorder is fairly prevalent among alcohol abusing/dependent subjects. The objective of the present study was to investigate: (a) the incidence of social anxiety symptoms in inpatient alcoholics, (b) the effect of alcohol detoxification on these symptoms, and (c) whether a combined psychotherapeutic/mirtazapine treatment during the post-detoxification phase of alcoholism has a greater impact on the aforementioned symptoms than a non-pharmacological approach. METHOD: Social anxiety symptoms were assessed through the Liebowitz Social Anxiety Scale (LSAS) following a 4-5-week detoxification period in two groups: group A (n=21) that followed a detoxification protocol of cognitive-behavioral orientation and group B (n=33) that was assigned to mirtazapine in addition to the standard protocol. Concomitant psychopathology was monitored through the HARS and HDRS, and level of functioning through the GAS. RESULTS: A marked reduction of social anxiety symptoms was evidenced in both groups. However, patients on mirtazapine improved significantly more compared to controls. LIMITATIONS: A single measure of social anxiety, i.e., the LSAS was used. Also, a longer follow-up period is needed to ascertain remission of social anxiety symptoms. CONCLUSIONS: The present study found a rather high incidence of social anxiety symptoms in inpatient alcoholics which subsided following alcohol detoxification; moreover, it provides preliminary evidence that a combined psychotherapeutic/mirtazapine treatment (30-60 mg/daily) has a greater impact on the aforementioned symptoms than non-pharmacological treatment alone.
Assuntos
Antagonistas Adrenérgicos alfa/uso terapêutico , Alcoolismo/complicações , Alcoolismo/terapia , Mianserina/análogos & derivados , Mianserina/uso terapêutico , Transtornos Fóbicos/psicologia , Psicoterapia , Adulto , Alcoolismo/psicologia , Terapia Combinada , Feminino , Humanos , Inativação Metabólica , Incidência , Pacientes Internados , Masculino , Pessoa de Meia-Idade , Mirtazapina , Transtornos Fóbicos/epidemiologia , Transtornos Fóbicos/etiologiaRESUMO
The objective of the present study was to determine whether a combined psychotherapeutic-psychopharmacological (with mirtazapine) treatment of collateral anxiety and depressive symptomatology during the post-withdrawal phase of alcoholism facilitates the process of alcohol detoxification, which is a decisive stage in the treatment of alcohol-dependent individuals. For that purpose, the rate of remission of anxiety and depressive symptoms over a 4-week detoxification period was evaluated between two groups: the first group followed a standard detoxification protocol (n = 33) and the second group was assigned to mirtazapine in addition to standard treatment (n= 35). A marked reduction of anxiety and depressive symptoms was demonstrated in both groups. However, patients on mirtazapine improved more and at a faster rate compared to controls. Thus, mirtazapine, used adjunctively to short-term psychotherapy, may help the detoxification process by minimizing physical and subjective discomfort. Consequently, it may improve patient compliance in alcohol detoxification programs and facilitate the initial phase treatment of alcohol abuse dependence.
Assuntos
Alcoolismo/terapia , Antidepressivos Tricíclicos/uso terapêutico , Mianserina/análogos & derivados , Mianserina/uso terapêutico , Síndrome de Abstinência a Substâncias/terapia , Adolescente , Adulto , Alcoolismo/tratamento farmacológico , Alcoolismo/psicologia , Terapia Combinada , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Mirtazapina , Escalas de Graduação Psiquiátrica , Psicoterapia , Síndrome de Abstinência a Substâncias/tratamento farmacológico , Temperança/psicologia , Resultado do TratamentoRESUMO
Obsessive-compulsive disorder (OCD) is often the anxiety disorder that affects approximately 2% of the population. This disorder is associated with significant morbidity and dysfunction, and is included in the World Health Organization list of the ten most disabling medical illnesses. The therapeutic response of patients with OCD is relatively poor compared with that of other mental disorders. Pharmacological interventions for OCD have focused on modulating primarily serotonin function and secondarily dopamine neurotransmission. Augmentation treatment has been the subject of several studies in treatment-resistant obsessive compulsive disorder (OCD). We hypothesized that medications with a dual action on the melatoninergic and serotoninergic systems may be of use in treatment-resistant OCD. In this open label study we investigated the efficacy and safety of agomelatine augmentation in treatment-resistant OCD. Twelve patients, aged 18-50, fulfilling OCD criteria, having failed to respond to adequate treatment with a Serotonine Reuptake Inhibitor for at least 16 weeks, were assigned to receive agomelatine augmentation. Subjects were assessed with the Yale-Brown Obsessive Compulsive Scale (Y-BOCS), and were screened for treatment-emergent side effects at baseline and week 16 of treatment. We excluded patients with comorbid psychopathology, serious medical comorbidity, current or past history of substance abuse and severe personality disorders as well as patients receiving psychotherapy in addition to psychopharmacological treatment. Agomelatine augmentation lead to net improvement in Y-BOCS and its obsession and compulsion subscales after 16 weeks of treatment (all p<0.005). Agomelatine augmentation was well-tolerated and none of the patients dropped-out. Treatment-related adverse events were recorded as follows: (n, %): nausea: 1 (8.3%), headache 4 (33.3%), dizziness: 3 (25%) and somnolence: 2 (16.7%). The present case series study has several limitations due to its open-label design and the absence of a placebo or active control group. The small number of patients further limits the impact of our findings. The present case series study showed that a 16 week add-on treatment with agomelatine, achieved on average a 25% improvement in Y-BOCS in refractory to treatment OCD patients; side effects were mild, and none of the patients dropped out throughout the 16-week study period. Agomelatine could be efficacious and well tolerated as an augmenting agent in refractory to treatment OCD. The unique pharmacological profile of agomelatine and its dual action on serotoninergic and melatoninergic receptors may be of interest in this difficult-to-treat illness. Further controlled studies are warranted to explore the efficacy of agomelatine, as well as the potential role of circadian rhythm modulation both in the pathophysiology and treatment of OCD.
Assuntos
Acetamidas/uso terapêutico , Transtorno Obsessivo-Compulsivo/tratamento farmacológico , Acetamidas/efeitos adversos , Adulto , Antipsicóticos/uso terapêutico , Quimioterapia Combinada , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Escalas de Graduação Psiquiátrica , Inibidores Seletivos de Recaptação de Serotonina/uso terapêutico , Resultado do TratamentoRESUMO
There is evidence that GABAergic anticonvulsants can be efficacious in the treatment of alcohol dependence and in the prevention of alcohol relapse because these agents act on the substrate that is involved in alcoholism. Tiagabine, a selective GABA transporter1 reuptake inhibitor, may be a promising candidate for the treatment of alcohol-dependent individuals. In this randomized, open pilot study, we aimed to investigate the efficacy and tolerability of tiagabine as adjunctive treatment of alcohol-dependent individuals (N = 60) during the immediate post-detoxification period and during a 6-month follow-up period following alcohol withdrawal. A control non-medicated group of alcohol-dependent individuals (N = 60) was used for comparisons in terms of anxiety and depressive symptoms, craving and drinking outcome. Although a steady improvement in terms of psychopathology, craving and global functioning was observed in both groups throughout the study, subjects on tiagabine improved significantly more compared to the control subjects (P < 0.001). Furthermore, the relapse rate in the tiagabine group was lower than in the control group (7 vs 14.3%). Tiagabine was well tolerated and only a minority of the participants reported some adverse effects in the beginning of tiagabine treatment. Results from this study suggest that tiagabine is a safe and effective medication for the management of alcohol dependence when given adjunctively to a standard psychotherapy treatment. Further studies are warranted before definite conclusions can be reached.
Assuntos
Transtornos Relacionados ao Uso de Álcool/tratamento farmacológico , Inibidores da Captação de GABA/efeitos adversos , Inibidores da Captação de GABA/uso terapêutico , Ácidos Nipecóticos/efeitos adversos , Ácidos Nipecóticos/uso terapêutico , Adolescente , Adulto , Idoso , Transtornos do Sistema Nervoso Induzidos por Álcool/tratamento farmacológico , Ansiedade/tratamento farmacológico , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Projetos Piloto , Síndrome de Abstinência a Substâncias/tratamento farmacológico , Tiagabina , Adulto JovemRESUMO
BACKGROUND: Nowadays percutaneous endoscopic gastrostomy (PEG) is widely available, but patient-selection criteria and quality of informed consent are debated. The aims of this retrospective study were to evaluate the quality of information given to the decision-makers (relatives) and determine the overall acceptance of the procedure by the patients' family. METHODS: The relatives of patients with PEG were interviewed by telephone, using a structured questionnaire. They (n = 55; 36% spouses, 34% children, 30% other) gave information about themselves and the patient (34 males, 21 females, median age 69, range 16-92 years) who underwent PEG tube placement for eating disorders or dysphagia. RESULTS: At the time of evaluation 30/55 (54.6%) patients had died. The cumulative median survival was significantly longer in patients younger than 75 years by 58 days (p = 0.009). Relatives believed that PEG could improve the patients' quality of life (56%) or/and the underlying disease. Although 93% of the decision-makers considered that their opinion had been taken into account when the procedure was done, 25% said that they had not adequately been informed about alternative methods and the complications of the procedure (38%). 54% said that the procedure had improved the quality of life of the family. Most of the decision-makers believed that their decision was correct (87%) and they would recommend PEG (84%) to other patients suffering from dysphagia. CONCLUSION: Though several decision-makers were not satisfied with the quality of information given before informed consent, the overall acceptance of the PEG placement for nutritional support is high.